121results about How to "Improve dysfunction" patented technology

Techniques are provided for use in controlling rate-adaptive pacing within implantable medical devices such as pacemakers or implantable cardioverter-defibrillators (ICDs). In one example, a force-frequency relationship is determined for the heart of the patient, which is representative of the relationship between cardiac stimulation frequency and myocardial contractile force. To this end, various parameters are detected for use as surrogates for contractile force, including selected systolic pressure parameters and cardiogenic impedance parameters. Rate-adaptive pacing is then controlled based on the detected force-frequency relationship to, for example, deactivate rate-adaptive pacing if the slope and / or abscissa of the force-frequency relationship indicates significant contractility dysfunction within the patient. In other examples, rather than deactivating rate-adaptive pacing, control parameters are adjusted to render the rate-adaptive pacing less aggressive. In still other examples, trends in the slope and / or abscissa of the force-frequency relationship are monitored to detect contractility dysfunction and / or heart failure and titrate medications accordingly.

A method and apparatus for treatment of hypertension with electrostimulation of peripheral nerves. Treatment is performed by periodically stimulating a nerve such as a median nerve. Apparatus for stimulation is permanently implanted in the body. The nerve is stimulated by electric current applied to electrodes that are placed near the target nerve or the muscle innervated by the target nerve.

A method and apparatus for treatment of hypertension with electrostimulation of peripheral nerves. Treatment is performed by periodically stimulating a nerve such as a median nerve. Apparatus for stimulation is permanently implanted in the body. The nerve is stimulated by electric current applied to electrodes that are placed near the target nerve or the muscle innervated by the target nerve.

The invention defines interdependent biofactors and biomolecules, and clinically useful formulations that are comprised of them. The active agents are demonstrated to be complementary in their physiologic functions especially as these relate to the quenching of free radicals and to the support of endothelial physiology, the reduction of hyperinsulinemia and improvements in vascular health. The active components of the invention are selected for inclusion in precise combinations specifically because they improve these various conditions and physiological functions, and by so doing reduce a variety of risks associated with hearing loss and tinnitus. The resulting enhancement of general systemic vascular health, improvement in local VIIIth nerve vascular health, modulation of conditions surrounding blood fluid dynamics, the consequences of hyperinsulinemia, and improvements in free radical defenses, all reduce the potential for cochlear hair cell death and VIIIth nerve atrophy, and the hearing loss and possible deafness that accompany them.

The invention defines interdependent biofactors and biomolecules, and clinically useful formulations that are comprised of them. The active agents are demonstrated to be complementary in their physiologic functions especially as these relate to the quenching of free radicals and to the support of endothelial physiology, the reduction of hyperinsulinemia and improvements in vascular health. The active components of the invention are selected for inclusion in precise combinations specifically because they improve these various conditions and physiological functions, and by so doing reduce a variety of risks associated with hearing loss and tinnitus. The resulting enhancement of general systemic vascular health, improvement in local VIIIth nerve vascular health, modulation of conditions surrounding blood fluid dynamics, the consequences of hyperinsulinemia, and improvements in free radical defenses, all reduce the potential for cochlear hair cell death and VIIIth nerve atrophy, and the hearing loss and possible deafness that accompany them.

Described herein, in certain embodiments, are devices and methods for modulating the electrical activity of a brain in a targeted manner using a weak magnetic field, generally field with a strength of less than about 100 Gauss. The magnetic field is varied over time in a periodic manner, generally with a frequency tuned to specifically affect one of the intrinsic frequencies of the brain, optionally the alpha frequency. The “Low Field Magnetic Stimulation” devices and methods described herein modulate the electrical activity of a brain without requiring medication. Methods and devices described herein gently “tune” the brain and affect mood, focus, and cognition of human subjects.

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element. The catheter is introduced into the patient, and target tissue is treated with the at least one treatment element. The target tissue comprises mucosal tissue of the small intestine, and the medical procedure can be configured to treat one or more diseases or disorders based on a measured physiologic parameter of the patient.

The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.

The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.

The present invention is related to compositions and methods for treating or reducing the likelihood of a migraine, reducing the severity of migraine, reducing the frequency of migraines, reducing the duration of migraine, and ameliorating the symptoms of a migraine. The methods and compositions of the present invention may also be used to treat or prevent a condition characterized by increased cardiovascular risk or endothelial dysfunction and musculoskeletal symptoms.

A computer-based method of determining a functional assessment of at least one organ having secretional or excretional functions, such as a liver or kidneys, of a human is disclosed. The method comprises processing a four-dimensional (4D) image data set of said human comprising data for an assessment of said organ function, wherein said 4D image data is acquired by an image modality; and wherein said processing said 4D image data comprises performing a deconvolutional analysis (DA) comprising a matrix inversion using singular value decomposition (SVD) based on said 4D image data.

Disclosed is a medicine for treating cervical disease and its preparation, wherein the medicine is prepared from Chinese medicinal herbs including prepared rehmannia root, gastrodia tuber, myrrh, homalomena rhizoma, frankincense, fleece-flower root, kudzu vine root, cassia twig, and musk through wine extraction, mixing with white spirit and musk.

It is intended to provide a novel agent for promoting the recovery from dysfunction after the onset of a central neurological disease or an agent for enhancing and / or promoting the effect of rehabilitation for functional recovery. Namely, an agent for promoting the recovery from dysfunction after the onset of a central neurological disease which contains, as the active ingredient, a compound capable of simultaneously and selectively enhancing neurotransmission by serotonin and neurotransmission by norepinephrine; and an agent for enhancing and / or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease which contains, as the active ingredient, a compound capable of simultaneously and selectively enhancing neurotransmission by serotonin and neurotransmission by norepinephrine. It is useful to provide the excellent agent for promoting the recovery from dysfunction after the onset of a central neurological disease and the agent for enhancing and / or promoting the effect of rehabilitation for functional recovery as described above. These drugs are also useful as safe drugs because of being free from anticholinergic effect causing side effects, drug dependence or effects on the circulatory organs.

To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance or ameliorate the pathosis, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant or, a fraction thereof containing the compound as an active ingredient.

The invention discloses healthcare food for comprehensively improving disorder of spleen and stomach and intestinal tract and preparation method of the healthcare food. The defects that the spleen and stomach and intestinal tract are not regarded as an organic integer to be comprehensively conditioned, the condition effect is not ideal, and the applicability is not strong in the prior art are overcome. The technical scheme is as follows: the food is characterized by comprising the following raw materials in parts by weight: 0.1-5 parts of galatooligosaccharide, 0.5-6 parts of fructo-oligose, 0.5-8 parts of polydextrose, 0.1-1.5 parts of dioscorea opposite extract, 0.1-2.5 parts of malt and 0.5-3 parts of red dates. The preparation method comprises the following steps: (1) taking the malt and red dates, removing impurities, cleaning, washing and drying the malt and red dates, and grinding into 60-80-mesh fine powder; (2) uniformly mixing the fine powder obtained in the step (1) with the galatooligosaccharide, the fructo-oligose, the polydextrose and the dioscorea opposite extract; (3) pelletizing the mixed fine powder by using edible alcohol with concentration of 90-95%; (4) sterilizing the particles for 1-1.5 hours at 60-75 DEG.C; and (5) screening the sterilized particles through a 60-80-mesh sieve, filling in a composite aluminum film bag to store so as to obtain the finished product.

A method for aiding cerebral recovery following neurodegeneration, particularly after a stroke, in a mammal, by administration of nefiracetam is disclosed. This method of treatment allows an improvement in the recovery from stroke.

Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.

A therapeutic agent for voiding dysfunction associated with neurogenic bladder where said agent contains tamsulosin or a pharmaceutically acceptable salt thereof.

A Chinese medicine in the form of particle for treating the minimal brani dysfunction (MBD) of children is prepared from 11 Chinese-medicinal materials including rehmannia root, white peony root, ophiopogon root, pilose osiabell root, etc.

The present invention provides a pharmaceutical composition for the treatment of diastolic congestive heart failure containing at least one active ingredient selected from the group consisting of icosapentaenoic acid, a pharmaceutically acceptable salt thereof, and an ester thereof.

The present invention provides a preventive or a remedy for penile erectile dysfunction, which promotes blood-flow in a penile sponge body over long time and thus induces erection while showing high safety without any adverse effect on a body as a whole, when externally administered to a penis. Use of a drug of the present invention enables to prevent or treat male penile erectile dysfunction and, at the same time, overcome a problem of female insertion impediment caused by increased resistance due to vaginal secretion disorder. Namely, a sexual life of patients (including aged persons) having coital dysfunction can be normalized and thus QOL can be improved.

The invention is: a natural active water-soluble protein and polypeptide and a preparation method thereof. Using selected natural protein-rich raw materials, through grinding and pulping, using a protein extractant to extract crude protein, using a solvent for simple degreasing, and then enzymatic fine degreasing and enzymatic fine decellulose to obtain refined protein pulp, and then Use end-capping agents to protect useful protein end groups, then use local acidifiers to locally acidify the long chain of proteins, then use acid protease for preliminary enzymatic hydrolysis, neutral protease for deep enzymatic hydrolysis, and timely detect the molecular weight, molecular weight distribution and amino acids of water-soluble proteins and polypeptides Content and other control indicators, when the control indicators reach the required value, stop the enzymatic hydrolysis reaction, then add deodorizing agent to remove odor, decolorizing agent to decolorize, filter and separate through filter, freeze or spray dry to obtain the finished product of natural active water-soluble protein and polypeptide .

The invention relates to a traditional Chinese medicine for treating chloasma; the invention is a medicament prepared by the following raw materials by weight proportion through a conventional method: 5-8g of angelica, 8-10g of safflower, 8-10g of figwort, 5-8g of radix bupleuri, 5-10g of trichosanthin, 8-10g of red paeonia, 5-10g of rhizoma anemarrhenae, 10-20g of radix astragali, 8-12g of fried atractylodes rhizome, 6-10g of prepared nutgrass galingale rhizome and 1.5-3g of liquorice. The invention has rapid curative effect, short treatment course, high cure rate, low cost but no toxic and side effects at all; through the clinical application of patients, the cure rate reach 95 percent and the total effective rate can reach over 98 percent. Furthermore, the invention has significant treatment effect for the patients with stain and irregular menstruation. .

The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.

N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide and salts thereof are used for the preparation of medicaments, particularly of pharmaceutical compositions containing it as an active ingredient, for the treatment of neurodegeneration, in particular in post-stroke human patients. The early administration of nefiracetam or its salt in said pharmaceutical compositions after a stroke allows an improvement of the Acivities of Daily Living and the recovery, or at least in improvement in the recovery of, post-stroke patients.

The present invention belongs to the field of Chinese medicine preparation technology, and is especially arrhythmia treating Chinese medicine preparation prepared with flavescent sophora root 3-9 weight portions, red sage 3-12 weight portions, spikenard 2-6 weight portions, Yunnan tuckahoe 3-10 weight portions, prepared licorice 3-8 weight portions, dry ginger 1-6 weight portions and magnet 3-9 weight portions. The preparation process includes the following steps: 1. crushing dry ginger, red sage, spikenard and Yunnan Tuckahoe into meal; 2. decocting magnet for 2-4 times to obtain decoction; 3. soaking flavescent sophora root and prepared licorice in the decoction, decocting for 2-4 times, filtering and concentrating to obtain extractum; 4. mixing the meal and the extractum, drying and grinding into powder; and 5. sterilizing the powder and filling into 0# capsule. The Chinese medicine preparation has high curative effect on arrhythmia.